TY - JOUR
T1 - Comparing organ-at-risk doses for high-dose-rate vaginal brachytherapy between three different planning workflows
AU - Gruhl, J. D.
AU - Zheng, D.
AU - Longo, J. L.
AU - Enke, C.
AU - Wahl, A. O.
N1 - Publisher Copyright:
© 2016 American Brachytherapy Society
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Purpose The aim of this study was to compare the organ-at-risk doses to the rectum and the bladder in postoperative endometrial cancer patients who receive high-dose-rate vaginal brachytherapy (HDR-VB), when using three different methods of treatment planning: (Workflow A) individualized treatment planning before every fraction, (Workflow B) individualized treatment planning for first fraction only), and (Workflow C) using a template plan based on applicator choice and prescription specifics without patient-specific imaging or planning (standardized template approach). Methods and Materials Alternative plans were retrospectively created using workflows B and C for 22 patients who previously received postoperative HDR-VB using a vaginal cylinder and planned using Workflow A for endometrial cancer. The rectum and bladder were contoured on the CTs used for each fraction for dose comparison between the three methods. D50, D2cc, D1cc, D0.1cc, and V100 of the bladder and the rectum were compared using the two-sided Wilcoxon signed-rank test. Results A total of 123 fractions were available for comparison. For Workflow A vs. Workflow B, there was no significant difference for any rectal or bladder dosimetric parameter. For Workflow A vs. Workflow C, Workflow A delivered a significantly higher median dose to the rectum than Workflow C for D50, D2cc, D1cc, and V100. Workflow C delivered a significantly higher dose to the bladder than Workflow A: D2cc, D1cc, D0.1cc, and V100. However, the magnitudes of the differences were small; the dose index difference was >75 cGy for only two fractions. Conclusion Plan standardization in HDR-VB may result in considerable time and cost savings with minimal organ-at-risk dose differences.
AB - Purpose The aim of this study was to compare the organ-at-risk doses to the rectum and the bladder in postoperative endometrial cancer patients who receive high-dose-rate vaginal brachytherapy (HDR-VB), when using three different methods of treatment planning: (Workflow A) individualized treatment planning before every fraction, (Workflow B) individualized treatment planning for first fraction only), and (Workflow C) using a template plan based on applicator choice and prescription specifics without patient-specific imaging or planning (standardized template approach). Methods and Materials Alternative plans were retrospectively created using workflows B and C for 22 patients who previously received postoperative HDR-VB using a vaginal cylinder and planned using Workflow A for endometrial cancer. The rectum and bladder were contoured on the CTs used for each fraction for dose comparison between the three methods. D50, D2cc, D1cc, D0.1cc, and V100 of the bladder and the rectum were compared using the two-sided Wilcoxon signed-rank test. Results A total of 123 fractions were available for comparison. For Workflow A vs. Workflow B, there was no significant difference for any rectal or bladder dosimetric parameter. For Workflow A vs. Workflow C, Workflow A delivered a significantly higher median dose to the rectum than Workflow C for D50, D2cc, D1cc, and V100. Workflow C delivered a significantly higher dose to the bladder than Workflow A: D2cc, D1cc, D0.1cc, and V100. However, the magnitudes of the differences were small; the dose index difference was >75 cGy for only two fractions. Conclusion Plan standardization in HDR-VB may result in considerable time and cost savings with minimal organ-at-risk dose differences.
KW - Endometrial cancer
KW - HDR vaginal brachytherapy
KW - Organ-at-risk doses
KW - Vaginal brachytherapy
UR - http://www.scopus.com/inward/record.url?scp=85009265642&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009265642&partnerID=8YFLogxK
U2 - 10.1016/j.brachy.2016.11.008
DO - 10.1016/j.brachy.2016.11.008
M3 - Article
C2 - 28039010
AN - SCOPUS:85009265642
SN - 1538-4721
VL - 16
SP - 373
EP - 377
JO - Brachytherapy
JF - Brachytherapy
IS - 2
ER -